
Sustained Clinical Response Rates of 66.7% with Ridinilazole vs. 42.4% with Vancomycin Ridinilazole to ...

BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage ...
Click to continue to site. Closing